Fatigue Associated with Trastuzumab Deruxtecan in Solid Tumors: A Meta-Analysis and Pharmacovigilance Signal Detection Study
T-DXd is associated with substantially increased fatigue risk and high incidence across solid tumors. Early detection, proactive management, and routine monitoring of patientreported outcomes are recommended to support treatment adherence and quality of life.
Authors
- Yongxin Li (ORCID: https://orcid.org/0000-0002-2478-6162)
- Yuyao Tang
- Yinyin Ye (ORCID: https://orcid.org/0000-0003-0625-9657)
- Xinlong Tao (ORCID: https://orcid.org/0000-0003-4494-484X)
- Cheng-Rong Zhang
- Jiuda Zhao
- Qianyue Ma
Institutions
- Qinghai University Affiliated Hospital (CN)
Publication Details
- Journal
- Current Drug Safety
- Published
- 2026-01-05
- DOI
- https://doi.org/10.2174/0115748863400146251007114813
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00